ASB8

Across TCGA pan-cancer cohorts, ASB8 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ASB8 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ASB8 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ASB8 expression acts as an unfavorable survival marker.

LSCC, GBM, and LUAD are the cancer types where ASB8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.765	1.000	.001	22	view →
GBM	OS	Median	All	0.230	0.680	.011	8	view →
LUAD	OS	Median	All	0.599	0.936	.020	8	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ASB8–LSCC (OS)

Open the LSCC breakdown →